- Remove All
- Your shopping cart is currently empty
3-Deoxyglucosone(3-Deoxy-D-glucosone) is synthesized by the intermediate pathway of the melad and polyol reactions.3-Deoxyglucosone reacts rapidly with protein amino groups to form advanced glycosylated end proteins (AGEs).3-Deoxyglucosone inactivates glutathione peroxidase and synergizes with low glucose to enhance GLP-1 secretion.3-Deoxyglucosone is used as a biomarker for diabetes mellitus.3-Deoxyglucosone has been shown to be an inhibitor of GLP-1 secretion in the presence of low glucose. 3-Deoxyglucosone inactivates glutathione oxidase, synergizes with low glucose to enhance GLP-1 secretion, and can be used as a biologic marker for diabetes.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $188 | In Stock | |
5 mg | $478 | In Stock | |
50 mg | Inquiry | Backorder |
Description | 3-Deoxyglucosone(3-Deoxy-D-glucosone) is synthesized by the intermediate pathway of the melad and polyol reactions.3-Deoxyglucosone reacts rapidly with protein amino groups to form advanced glycosylated end proteins (AGEs).3-Deoxyglucosone inactivates glutathione peroxidase and synergizes with low glucose to enhance GLP-1 secretion.3-Deoxyglucosone is used as a biomarker for diabetes mellitus.3-Deoxyglucosone has been shown to be an inhibitor of GLP-1 secretion in the presence of low glucose. 3-Deoxyglucosone inactivates glutathione oxidase, synergizes with low glucose to enhance GLP-1 secretion, and can be used as a biologic marker for diabetes. |
In vitro | 3-Deoxyglucosone (80 ng/ml-1000 ng/ml; 1 hour; STC-1 cells) induces a 1.23-fold increase in GLP-1 secretion at 300 ng/ml and 1000 ng/ml, while 80 ng/ml shows no effect. At 300 ng/ml, 3DG significantly elevates intracellular Ca2+ levels, as measured by Fluo-3/AM (2.5 μM for 30 mins), but does not affect intracellular cAMP in a cAMP Elisa assay. Additionally, 300 ng/ml 3DG significantly enhances TAS1R2, TAS1R3, and TRPM5 protein expression under both glucose-free and high conditions.[1] |
In vivo | 3-Deoxyglucosone (20 mg/kg; intragastric administration; single dose) induces a deterioration in glucose tolerance, as evidenced by an increased Area Under the Curve (AUC). Plasma glucagon levels do not show significant differences. The administration of 3-Deoxyglucosone leads to the development of impaired glucose regulation (IGR) accompanied by evident dysfunction of pancreatic islet cells in both Kunming mice and SD rats.[2] 3-deoxyglucosone (5-50 mg/kg; gastric gavage; once daily; 2 weeks; SD rats) exhibits significant increases in the upper small intestine (1.4-fold), lower small intestine (1.4-fold), ileum (1.4-fold), and colon (two-fold) compared to basal levels in their respective control groups. Additionally, there is a noteworthy decrease in the protein expressions of TAS1R2, TAS1R3, and TRPM5 observed in both the duodenum and colon.[3] |
Cell Research | Cell Line: STC-1 cells. Concentration: 300?ng/ml. Incubation Time: 1 hour [1] |
Animal Research | Animal Model: SD rats. Dosage: 5, 20 and 50 mg/kg. Administration: oral administration; once daily; 2 weeks [3] |
Alias | 3-Deoxy-D-glucosone, 2-keto-3-Deoxyglucose |
Molecular Weight | 162.14 |
Formula | C6H10O5 |
Cas No. | 4084-27-9 |
Smiles | [C@H](CC(C=O)=O)([C@@H](CO)O)O |
Relative Density. | 1.406g/cm3 |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.